Enliven Therapeutics (ELVN) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 100.0% versus a gain of 58.3%. Over five years, ELVN leads with a +177.5% price change compared with -30.7% for RCUS. Arcus Biosciences is the larger company by market cap ($3.00 billion vs $2.98 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | RCUS |
|---|---|---|
| Share price | $40.63 | $23.83 |
| Market cap | $2.98B | $3.00B |
| 1-day change | -1.76% | -2.81% |
| YTD return | +163.83% | 0.00% |
| 1-year return | +99.95% | +58.34% |
| 5-year return | +177.53% | -30.71% |
| EPS (TTM) | $-1.67 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $247.00M |
| Revenue growth (YoY) | — | -4.26% |
| Net income (latest FY) | $-103.69M | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $62.32 | $31.74 |
| 52-week low | $14.79 | $14.26 |
| Distance from 52-week high | -34.80% | -24.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +81.32% | +67.48% |
| Average volume | 1.12M | 1.34M |
| Shares outstanding | 73.27M | 125.77M |
| Employees | 67 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed RCUS by 41.6 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
ELVN vs RCUS FAQ
Which is bigger, Enliven Therapeutics or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $3.00B compared with $2.98B for Enliven Therapeutics (ELVN).
Which stock has performed better over the past year, ELVN or RCUS?
ELVN returned +99.95% over the past 12 months, compared with +58.34% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.